PATENT CLAIM ANALYSIS

Application Number: 16195661
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-10
Patent Classification: ["514", "001900"]

Abstract:
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.

Claim (Index 32):
An improved kit for determining the predisposition of a human patient with lipoatrophy to respond to treatment with leptin, leptin analog or leptin derivative, the improvement comprising means for determining whether the leptin level of the patient prior to said leptin treatment is:\n (i) less than or equal to approximately 2 ng/ml if said patient is male, or (ii) less than or equal to approximately 4 ng/ml if said patient is female.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.55357
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10623189', '13103294', '12995842', '11821221', '10286947']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.773815062971067
- 35 USC 102 Novelty (BERT): 0.5933115735938267
- Combined Prediction Score: 0.7557647140333429
- Mean Citation Score: 356.92271800000015
- Max Citation Score: 521.53766
- Similarity Product: 455.1938380633521

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test